Regarding PMX, a newer antifolate agent, only a few studies of TYMS, MTHFR, and SLC19A1 polymorphisms in NSCLC were published to date.16,17 Very little is known about the influence of these polymorphisms on response to treatment with PMX in MPM.18 Here, TYMS is linked to non-small cell lung carcinoma.